Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919113 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A Phase 2 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00919113: Completed Phase 2 study, sponsored by Watson Pharmaceuticals.
NCT00919113 is a Phase 2 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00919113, a Phase 2 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
Primary Outcome
subjects that indicated "markedly improved" or "moderately improved" on the GRA, LOCF
Interventions
- DRUG Placebo
- DRUG 2% sodium chondroitin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00919113 record still lists
NCT00919113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00919113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00919113 about?
NCT00919113 is a clinical study titled "Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome". A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
What is the current status of trial NCT00919113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2009-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00919113?
The interventions under investigation include: Placebo (DRUG), 2% sodium chondroitin sulfate (DRUG).
Who is sponsoring clinical trial NCT00919113?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00919113's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia